Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $37.73 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.